Aclaris Therapeutics, Inc. (ACRS)
Automate Your Wheel Strategy on ACRS
With Tiblio's Option Bot, you can configure your own wheel strategy including ACRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACRS
- Rev/Share 0.1453
- Book/Share 1.1771
- PB 1.3083
- Debt/Equity 0.0
- CurrentRatio 5.0567
- ROIC -0.7973
- MktCap 166752740.0
- FreeCF/Share -0.3935
- PFCF -3.4628
- PE -1.4475
- Debt/Assets 0.0
- DivYield 0
- ROE -0.9241
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ACRS | Piper Sandler | -- | Overweight | -- | $6 | July 10, 2025 |
| Initiation | ACRS | Wedbush | -- | Outperform | -- | $8 | May 28, 2025 |
| Resumed | ACRS | Cantor Fitzgerald | -- | Overweight | -- | -- | March 18, 2025 |
| Upgrade | ACRS | H.C. Wainwright | Neutral | Buy | -- | $20 | Dec. 23, 2024 |
News
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
Published: June 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, June 30, 2025. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market capitalization.
Read More
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company's potential best-in-class investigational bispecific anti-TSLP/IL-4R antibody.
Read More
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
Published: May 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June.
Read More
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris' Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright “HCW@Home” series. The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT.
Read More
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.24 per share a year ago.
Read More
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for …
Read More
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics' ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases.
Read More
About Aclaris Therapeutics, Inc. (ACRS)
- IPO Date 2015-10-06
- Website https://www.aclaristx.com
- Industry Medical - Diagnostics & Research
- CEO Neal S. Walker D.O.,
- Employees 61